Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Nicolas M Furiak
Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States
Cost Effectiveness and Resource Allocation
Health Policy
Related publications
Cost-Effectiveness Analysis of Lurasidone and Olanzapine in the Treatment of Schizophrenia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Change in Level of Productivity in the Treatment of Schizophrenia With Olanzapine or Other Antipsychotics
BMC Psychiatry
Psychiatry
Mental Health
Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia
Srpski Arhiv Za Celokupno Lekarstvo
Medicine
Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics
BMC Psychiatry
Psychiatry
Mental Health
Cost-Effectiveness Analysis Evaluating Fidaxomicin Versus Oral Vancomycin for the Treatment of Clostridium Difficile Infection in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia
Journal of Medical Economics
Health Policy
Cost-Effectiveness of Atypical Antipsychotics for the Treatment of Relapse Prevention for Bipolar Disorder: The Russian Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Adherence Patterns Among Patients Using Oral Atypical Antipsychotics and Other Medications
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Outpatient Prescriptions for Atypical Antipsychotics for African Americans, Hispanics, and Whites in the United States
Archives of General Psychiatry